ArticleFrontiers in microbiology2026
Effect of chemotherapy on gut microbiota in patients with colorectal cancer.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The gut microbiota plays a crucial role in digestion, energy conversion, immune regulation, and disease resistance. Research has established a link between gut microbiota and the development and progression of colorectal cancer(CRC), noting variations in their composition within and around tumors, and gut microbiota may impact the effectiveness of drug therapies. Chemotherapy remains the cornerstone of CRC treatment, yet studies exploring its relationship with gut microbiota are still limited. Methods: In this study, 16S rRNA sequencing was performed to profile gut microbiota alterations in 20 patients with colorectal adenocarcinoma before and after chemotherapy, and to further explore the association between first-line chemotherapy and gut microbiota composition. All participants received the FOLFOX6 chemotherapy regimen, and fecal samples were collected pre- and post-treatment, aiming to elucidate the connection between chemotherapy and gut microbiota by analyzing alterations in microbial composition, diversity, and richness across different chemotherapy cycles. Results: Following the first chemotherapy cycle, Chao1 index indacate there is a decline in gut microbiota richness among CRC patients (P < 0.01), along with notable shifts in microbial composition. Specifically, the phyla Firmicutes and Bacteroides decreased, while Proteobacteria, Actinobacteria, and Verrucomicrobia increased in abundance. Comparative analyses of gut microbiota profiles across sequential chemotherapy cycles revealed no statistically significant intergroup differences in the Chao 1 and Simpson indices (all P > 0.05). As chemotherapy cycles proceeded, the gut microflora did not show regular dynamic changes with the progression of chemotherapy cycles. KEGG functional gene prediction analysis indicated that chemotherapy-induced alterations in gut microbiota composition were linked to common chemotherapy side effects, including metabolic, immune, hematological, and neurological disturbances. Discussion: Our results demonstrate that chemotherapy has a certain correlation with the composition of gut microbiota in patients with colorectal cancer, and these microbial changes show a potential association with chemotherapy-related adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.